Screener
Amneal Pharmaceuticals, Inc. AMRX Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Amneal Pharmaceuticals, Inc.’s reported figures.
Based on the most recent quarter.
The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 5:19 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001723128-26-000031
FAQ
- What is Amneal Pharmaceuticals, Inc.'s debt-to-equity?
- Amneal Pharmaceuticals, Inc. (AMRX) reported debt-to-equity of 77.8× in Q2 2026.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s debt-to-equity?
- Over 3 years (2020 to 2023), Amneal Pharmaceuticals, Inc.'s debt-to-equity has grown at a 137.2% compound annual growth rate (CAGR), from 9.6× to 127.9×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about Amneal Pharmaceuticals, Inc.'s debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude